Unlock this StockReport nowClick to Unlock

Verona Pharma Share Price

VRP 46.2p 0.0  0.0%
22/07/19 2.00k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 3
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +17.5%

FINANCIAL BRIEF: For the three months ended 31 March 2019, Verona Pharma Plc revenues was not reported. Net loss decreased 64% to £5.4M. Lower net loss reflects Effective G/L on Derivatives - Hedg decrease from £9M (expense) to £0K, Effective G/L on Derivatives - Hedging increase from £0K to £1.6M (income), Foreign Exchange Gain/Loss decrease of 41% to £783K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -£0.14 to -£0.05. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: 2.31
(+399.31% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
3 brokers Broker Consensus Trend
Broker Recommendations for Verona Pharma
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 1

Named Brokers and Analysts
Stifel Nicolaus and Company, Incorporated Adam Walsh , Jefferies Peter Welford , Hardman & Company Martin Hall , Edison Investment Research , N+1 Singer Jens Lindqvist , Shore Capital Stockbrokers Tara Raveendran , GBC AG Cosmin Filker ,

Profile Summary

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.

Directors: Sven Karlsson (CEO) 60, Tara Rheault (VRD) , Ben Harber (SEC) , David Ebsworth (NEC) 61, Kenneth Cunningham (NED) 62, Vikas Sinha (NED) 53, Anders Ullman (NED) 59, Martin Edwards (NID) ,

No. of Employees: 14 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim March 31st, 2019
Incorporated February 24, 2005
Public Since March 30, 2005
Shares in Issue 105,326,637
Free Float 104.4m (99.1%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

VRP Share Price Performance VRP Share Price Quote
0.0  0.0%
Traded 3:44pm · Minimum 15 min delayed · NMS: 2.00k

Latest VRP News Announcements (delayed)

Upcoming VRP Events

Recent ↓
Tuesday 13th September, 2016
Half Year 2016 Verona Pharma PLC Earnings Release
Friday 22nd July, 2016
Verona Pharma PLC Ordinary Shareholders Meeting
Monday 27th June, 2016
Verona Pharma PLC Annual Shareholders Meeting
Monday 20th June, 2016
Verona Pharma PLC Secondary Public Offering Pricing
Friday 3rd June, 2016
Q4 2015 Verona Pharma PLC Earnings Release
Tuesday 3rd November, 2015
Verona Pharma PLC at  EBD BIO Europe- Fall
Thursday 11th June, 2015
Verona Pharma PLC Annual Shareholders Meeting
Wednesday 14th January, 2015
Verona Pharma PLC at EBD Biotech Showcase

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy VRP

Access VRP Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis